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Potassium plays an essential role in maintaining myocardial electrical stability. In the setting of myocardial ischemia, adrenergic stimulation activates the Na-K ATPase pump, lowering plasma potassium levels. 2 Several studies have suggested that in the setting of acute coronary syndrome (ACS), hypokalemia, typically defined as potassium levels <3.5 mEq/L (mmol/L), is associated with ventricular arrhythmias. [3] [4] [5] As a result, guidelines and experts have recommended a target potassium level of at least 4.0 mEq/L (mmol/L) in the setting of ACS. 6 Magnesium (Mg) plays an essential role in normal cardiac function, and low serum Mg levels may be associated with cardiac arrhythmias and sudden death. 7, 8 Magnesium deficiency is associated with significant life-threatening ventricular arrhythmias and sudden death, which may be treated with Mg supplementation. 9 Normal range for Mg is 0.7 to 1.0 mmol/L (1.5-2.0 mEq/L; 1.7-2.4 mg/dL), 10, 11 but the presence of serum Mg levels 2 mEq/L was associated with a significant increase in long-term cardiovascular mortality in patients with heart failure. 12 Magnesium has antiarrhythmic effects, and chronic Mg deficiency may predispose to arrhythmic events. 13 Several recent studies revealed an association between low serum Mg level and increased risk of atrial fibrillation 14 and sudden cardiac death. 15 Deficiency of Mg aggravates potassium wasting and also increases the adverse effects of hypokalemia on target tissues. 16 Therefore, early treatment of concomitant Mg deficiency is very important for effective treatment and prevention of complications of hypokalemia. 16 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and insulin treatment may also affect the level of potassium and Mg. 17, 18 However, there were no significant differences between groups in terms of drug therapy. Use of proton pump inhibitors (PPIs) is associated with low serum Mg concentrations. 19 However, authors did not mention whether their patients used PPIs.
